What Has Been Achieved in Cancer Proteomics

This gap between expectations and actual practice might have technical reasons  

Moreover, regulatory requirements were not fulfilled by most research groups because they were not considered for study design. For regulatory agencies and pharmaceutical companies to be convinced that combining 

About 40 small protein or peptide drugs are currently in clinical use with an estimated annual market of US 1 billion. These include insulin, parathyroid hormone (PTH), calcitonin, growth hormones, and so on [127], In oncology, several antibodies directed against surface proteins have entered the market over the last years, including herceptin in breast cancer, cetux-imab in CRC, imatinib in gastrointestinal stromal tumors, and so on. 

Indeed, there are still many technological challenges to meet the needs for high sensitivity, reproducibility, and throughput required for successful target discovery in cancer proteomics, including  

However, it is the hope that the rapid progress in sample preparation procedures and in proteomic technologies particularly improved mass spectrometer sensitivity will solve these problems. 

---